Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disorders

Research output: Contribution to journalArticle

364 Citations (Scopus)

Abstract

Epigenetic chromatin remodeling and modifications of DNA represent central mechanisms for regulation of gene expression during brain development and in memory formation. Emerging evidence implicates epigenetic modifications in disorders of synaptic plasticity and cognition. This review focuses on recent findings that HDAC inhibitors can ameliorate deficits in synaptic plasticity, cognition, and stress-related behaviors in a wide range of neurologic and psychiatric disorders including Huntington's disease, Parkinson's disease, anxiety and mood disorders, Rubinstein-Taybi syndrome, and Rett syndrome. These agents may prove useful in the clinic for the treatment of the cognitive impairments that are central elements of many neurodevelopmental, neurological, and psychiatric disorders.

Original languageEnglish (US)
Pages (from-to)57-64
Number of pages8
JournalCurrent Opinion in Pharmacology
Volume8
Issue number1
DOIs
StatePublished - Feb 2008

Fingerprint

Neuronal Plasticity
Nervous System Diseases
Epigenomics
Neurodegenerative Diseases
Cognition
Psychiatry
Rubinstein-Taybi Syndrome
Rett Syndrome
Histone Deacetylase Inhibitors
Chromatin Assembly and Disassembly
Huntington Disease
Gene Expression Regulation
Anxiety Disorders
Mood Disorders
Parkinson Disease
DNA
Brain
Inhibition (Psychology)
Cognitive Dysfunction

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Pharmacology

Cite this

Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disorders. / Abel, Ted; Zukin, R. Suzanne.

In: Current Opinion in Pharmacology, Vol. 8, No. 1, 02.2008, p. 57-64.

Research output: Contribution to journalArticle

@article{6bae97c1669b4a2a9a56e4d71d649acb,
title = "Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disorders",
abstract = "Epigenetic chromatin remodeling and modifications of DNA represent central mechanisms for regulation of gene expression during brain development and in memory formation. Emerging evidence implicates epigenetic modifications in disorders of synaptic plasticity and cognition. This review focuses on recent findings that HDAC inhibitors can ameliorate deficits in synaptic plasticity, cognition, and stress-related behaviors in a wide range of neurologic and psychiatric disorders including Huntington's disease, Parkinson's disease, anxiety and mood disorders, Rubinstein-Taybi syndrome, and Rett syndrome. These agents may prove useful in the clinic for the treatment of the cognitive impairments that are central elements of many neurodevelopmental, neurological, and psychiatric disorders.",
author = "Ted Abel and Zukin, {R. Suzanne}",
year = "2008",
month = "2",
doi = "10.1016/j.coph.2007.12.002",
language = "English (US)",
volume = "8",
pages = "57--64",
journal = "Current Opinion in Pharmacology",
issn = "1471-4892",
publisher = "Elsevier BV",
number = "1",

}

TY - JOUR

T1 - Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disorders

AU - Abel, Ted

AU - Zukin, R. Suzanne

PY - 2008/2

Y1 - 2008/2

N2 - Epigenetic chromatin remodeling and modifications of DNA represent central mechanisms for regulation of gene expression during brain development and in memory formation. Emerging evidence implicates epigenetic modifications in disorders of synaptic plasticity and cognition. This review focuses on recent findings that HDAC inhibitors can ameliorate deficits in synaptic plasticity, cognition, and stress-related behaviors in a wide range of neurologic and psychiatric disorders including Huntington's disease, Parkinson's disease, anxiety and mood disorders, Rubinstein-Taybi syndrome, and Rett syndrome. These agents may prove useful in the clinic for the treatment of the cognitive impairments that are central elements of many neurodevelopmental, neurological, and psychiatric disorders.

AB - Epigenetic chromatin remodeling and modifications of DNA represent central mechanisms for regulation of gene expression during brain development and in memory formation. Emerging evidence implicates epigenetic modifications in disorders of synaptic plasticity and cognition. This review focuses on recent findings that HDAC inhibitors can ameliorate deficits in synaptic plasticity, cognition, and stress-related behaviors in a wide range of neurologic and psychiatric disorders including Huntington's disease, Parkinson's disease, anxiety and mood disorders, Rubinstein-Taybi syndrome, and Rett syndrome. These agents may prove useful in the clinic for the treatment of the cognitive impairments that are central elements of many neurodevelopmental, neurological, and psychiatric disorders.

UR - http://www.scopus.com/inward/record.url?scp=38649124003&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38649124003&partnerID=8YFLogxK

U2 - 10.1016/j.coph.2007.12.002

DO - 10.1016/j.coph.2007.12.002

M3 - Article

C2 - 18206423

AN - SCOPUS:38649124003

VL - 8

SP - 57

EP - 64

JO - Current Opinion in Pharmacology

JF - Current Opinion in Pharmacology

SN - 1471-4892

IS - 1

ER -